What triggers an FDA Warning Letter for compounded GLP-1 marketing?

TL;DR

• What actually triggers these letters: marketing that implies a compounded semaglutide or tirzepatide product is the same as, or approved like, an FDA-approved drug — not the fact that it's compounded at all (FDA telehealth guidance).
• This is the third wave in under a year: roughly 80 warning letters plus 40 untitled letters in September 2025, 30 more on March 3, 2026, and 25 more the week of June 15, 2026 (National Law Review, June 18, 2026).
• FDA cites misbranding under FDCA Sections 502(a) and 502(n), 21 U.S.C. § 352(a) and (n), and judges the "net impression" of the whole marketing page, not just one flagged phrase.
• Below: 8 specific things to audit in your marketing and clinical-ops copy this week, in order.

Does compounding a GLP-1 drug make your marketing claims illegal? No — it's the claims themselves, not the compounding, that get companies cited.

That distinction is the whole ballgame right now. Telehealth companies keep getting warning letters not because they compound semaglutide or tirzepatide, which is legal under certain conditions, but because their landing pages, ads, and intake flows describe those compounded products as though FDA reviewed and approved them the same way it approved Wegovy or Zepbound. It didn't. FDA has now sent three separate waves of letters over this exact gap between what's legally permitted and what's being said out loud in marketing copy.

If your team runs marketing, clinical ops, or compliance for a telehealth or compounding business touching GLP-1s, here's what's actually triggering these letters and what to check before your company becomes wave four.

Why this wave is different

FDA sent 30 warning letters to telehealth companies on March 3, 2026, all targeting marketing of compounded GLP-1 products (FDA press release, March 3, 2026). During the week of June 15, 2026, FDA issued 25 more, citing the same category of claims under FDCA misbranding provisions (National Law Review, June 18, 2026). Before that: roughly 80 warning letters and 40 untitled letters in September 2025 — same source, same theory each time.

Three waves. One theory, repeated. Commissioner Marty Makary's departure in May 2026 didn't slow this track at all, which suggests an institutional priority inside CDER rather than one person's pet project (same National Law Review source).

The legal theory in plain language

Compounded drugs made under FDCA §503A (traditional pharmacy compounding) or §503B (outsourcing facilities) can be exempt from the normal new-drug-approval process. That exemption is real. But it covers the manufacturing pathway, not the marketing. Nothing in §503A or §503B lets a company tell patients the compounded product is equivalent to, reviewed like, or approved like an FDA-approved drug.

FDA evaluates the "net impression" of the marketing as a whole. Not one line. The whole page. A technically-accurate disclaimer buried in a footer doesn't rescue a headline that implies otherwise.

Phrases that have already triggered letters

Foley & Lardner's review of the March 2026 letters lists exact language FDA flagged (Foley & Lardner, March 12, 2026):

1. "Contains the active pharmaceutical ingredient in Wegovy" — implies equivalence to the approved product itself, not just a shared molecule.
2. "Generic Zepbound" — compounded drugs are never FDA-approved generics; calling one "generic" is a category error FDA treats as misbranding.
3. "FDA approved active pharmaceutical ingredients" — blurs the line between an approved ingredient and an unapproved finished product.
4. "Clinically studied and shown to deliver powerful results" — implies trial data behind the compounded product specifically, which usually doesn't exist.
5. "This FDA-approved treatment promotes safe, effective weight loss." Worth sitting with. The treatment being marketed is, by definition, the one that is not FDA-approved.

What else FDA is flagging

FDA's own telehealth guidance page goes further than the phrase list (FDA telehealth guidance):

• Branding or page design that makes the telehealth company look like the compounder, when a separate pharmacy actually does the work.
• Calling a compounded drug "generic" under any framing.
• "Clinically proven" language implying the compounded version performs the same as the trial-tested, approved drug.
• Describing a pharmacy or facility as "FDA-approved" or "FDA-licensed." FDA doesn't approve or license compounding pharmacies that way. Never has.

An audit list for your marketing and compliance teams, in order

Work through these this week. Not next quarter.

1. Pull every page mentioning semaglutide or tirzepatide and read it as a patient would, top to bottom. Note anywhere the net impression suggests FDA reviewed this specific product.
2. Search your site and ad copy for "generic," "FDA-approved," and "FDA-licensed." Any hit tied to a compounded product needs an immediate rewrite.
3. Check whether you name the approved reference drug (Wegovy, Zepbound, Ozempic, Mounjaro) near claims about your compounded product. Naming it isn't automatically illegal; pairing it with equivalence language is what's been cited.
4. Verify your compounding relationship is disclosed accurately. If a third-party 503A or 503B pharmacy compounds the product, your marketing shouldn't imply your company does.
5. Review "clinically studied" and "clinically proven" claims for whose data you're actually citing. Implying the reference drug's trial data applies to your formulation is the exact gap FDA is enforcing against.
6. Audit intake and consult scripts, not just marketing pages. Verbal claims from sales or telehealth visits create the same exposure as a landing page.
7. Have someone outside marketing — legal, compliance, or a regulatory consultant — read the pages cold, without the context your team built up over months of conversion-copy iteration.
8. Watch the adverse-event signal, not just the legal one. As of May 21, 2026, FDA had logged more than 1,700 adverse event reports tied to compounded semaglutide and tirzepatide (FDA GLP-1 concerns page). That's part of why a fourth wave is a reasonable bet, not a scare tactic.

None of this requires shutting down a compounded-GLP-1 business line. It requires marketing copy that matches what the product legally is — usually a smaller rewrite than teams expect once they sit down and do it.

FAQ

Does FDA ban telehealth companies from marketing compounded GLP-1 drugs at all?

No. The letters target specific claims of equivalence or approval, not the underlying practice of compounding or marketing it. A telehealth company can describe a compounded product accurately — including its compounded status, its ingredients, and appropriate use — without making the equivalence claims FDA has flagged.

Is a disclaimer at the bottom of the page enough to fix a misleading headline?

Not reliably. FDA evaluates the "net impression" of the marketing as a whole, meaning a strong claim in a headline or hero section isn't neutralized by a smaller disclaimer elsewhere on the same page.

How many warning letters has FDA sent over this specific issue so far?

Three waves as of this writing: roughly 80 warning letters plus 40 untitled letters in September 2025, 30 more on March 3, 2026, and 25 more the week of June 15, 2026 — all citing the same category of GLP-1 marketing claims.

Just got a Warning Letter? Start your free 30 days →

Sources: FDA press release, March 3, 2026, National Law Review, June 18, 2026, Foley & Lardner, March 12, 2026, FDA telehealth guidance, FDA GLP-1 concerns page. Byline: The Argus Regulatory Analysis Team. Published 2026-07-05.